(From left to right) Cellino co-founders Marinna Madrid, Nabiha Saklayen, and Matthias Wagner

February 1, 2021 08:00 AM EST

Khosla Ventures helps seed a next-gen regenerative medicines startup boasting AI-based stem cell culturing technology

Conner Mitchell

A startup in the bustling Boston-area biotech hub hopes its new technology has solved a time-consuming aspect of developing drugs that rely on cell therapy …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Khosla Ventures helps seed a next-gen regenerative medicines startup boasting AI-based stem cell culturing technology

Conner Mitchell

Sign up to read this article for free.

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Patient dies in Neurogene's Rett syndrome study

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Are programs with compounded GLP-1s safe for your population?

Khosla Ven­tures helps seed a next-gen re­gen­er­a­tive med­i­cines start­up boast­ing AI-based stem cell cul­tur­ing tech­nol­o­gy

Conner Mitchell

Sign up to read this article for free.

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Khosla Ventures helps seed a next-gen regenerative medicines startup boasting AI-based stem cell culturing technology

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Patient dies in Neurogene's Rett syndrome study

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Are programs with compounded GLP-1s safe for your population?